[ORGANIZATION]
SK Biopharmaceuticals
Featured in 3 tracked stories · first seen
Situations
SK Biopharm Opakalim licensing and clinical development
3 clusters · 9 sources · last updated
Latest: Biohaven faces investigation after FDA clinical hold on epilepsy drug
SK Biopharm entered an exclusive worldwide licensing agreement with Biohaven Bioscience Ireland for the epilepsy drug candidate Opakalim (BHV-7000) and its Kv7 Discovery Platform. The deal, valued at up to $795 million,
Also covered in
-
South Korean biotech firms approach first global blockbuster drugs
[BUSINESS] · 2 sources ·
-
SK Biopharmaceuticals deploys NVIDIA B200 AI cluster as Sugon announces 64-thread workstation
[TECHNOLOGY] · 2 sources ·